Oral Valganciclovir As Preemptive Therapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Yazarlar (9)
Prof. Dr. Vildan Ozkocaman Uludag University, Türkiye
Prof. Dr. Fahir Ozkalemkas Uludag University, Türkiye
Ridvan Ali
Uludag University, Türkiye
Uludag University, Türkiye
Doç. Dr. Yasemin KARACAN Uludag University, Türkiye
Doç. Dr. Tuba Ersal Uludag University, Türkiye
Hilmi Erdem Gozden
Uludag University, Türkiye
Uludag University, Türkiye
Tugcan Erus
Uludag University, Türkiye
Uludag University, Türkiye
Esra Kazak Uludag University, Türkiye
Halis Akalin
Uludag University, Türkiye
Uludag University, Türkiye
| Bildiri Türü | Tebliğ/Bildiri | Bildiri Dili | İngilizce |
| Bildiri Alt Türü | Özet Metin Olarak Yayınlanan Tebliğ (Uluslararası Kongre/Sempozyum) | ||
| Bildiri Niteliği | Web of Science Kapsamındaki Kongre/Sempozyum | ||
| Kongre Adı | |||
| Kongre Tarihi | / | ||
| Basıldığı Ülke | Basıldığı Şehir | ||
| UAK Araştırma Alanları |
|
||
| Özet |
| Introduction: Cytomegalovirus (CMV) infection remains one of the most important complications after allogeneic hematopoietic stem cell transplantation (AlloHSCT). Preemptive therapy with oral VGC or intravenous ganciclovir has replaced universal prophylaxis. We investigated the effect of oral VGC as preemptive therapy on CMV reactivation or infection in AlloHSCT. Patient & Methods: We retrospectively studied 30 consecutive adult recipients of HLA-identical sibling allogeneic peripheral blood stem cell transplant from June 2011 through June 2014 to analyze the safety and efficacy of preemptive therapy for the treatment of CMV infection. Among 30 patients we studied the results of 13 patients with CMV DNA positivity. All 13 recipients and their donors were seropositive for CMV Ig G status. Their diagnosis of pretransplantation were as 8 acute myeloid leukemia (61 %) and 5 acute lymphocytic leukemia (39 … |
| Anahtar Kelimeler |
